255 related articles for article (PubMed ID: 9222275)
1. Pharmacologic profile of ropinirole: a nonergoline dopamine agonist.
Tulloch IF
Neurology; 1997 Jul; 49(1 Suppl 1):S58-62. PubMed ID: 9222275
[TBL] [Abstract][Full Text] [Related]
2. Ropinirole: a dopamine agonist for the treatment of Parkinson's disease.
Kuzel MD
Am J Health Syst Pharm; 1999 Feb; 56(3):217-24. PubMed ID: 10030505
[TBL] [Abstract][Full Text] [Related]
3. Ropinirole in the symptomatic treatment of Parkinson's disease.
Brooks DJ; Torjanski N; Burn DJ
J Neural Transm Suppl; 1995; 45():231-8. PubMed ID: 8748630
[TBL] [Abstract][Full Text] [Related]
4. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.
Kulisevsky J; Pagonabarraga J
Drug Saf; 2010 Feb; 33(2):147-61. PubMed ID: 20082541
[TBL] [Abstract][Full Text] [Related]
5. Ropinirole and pramipexole, the new agonists.
Hobson DE; Pourcher E; Martin WR
Can J Neurol Sci; 1999 Aug; 26 Suppl 2():S27-33. PubMed ID: 10451757
[TBL] [Abstract][Full Text] [Related]
6. Ropinirole therapy for Parkinson's disease.
Pahwa R; Lyons KE; Hauser RA
Expert Rev Neurother; 2004 Jul; 4(4):581-8. PubMed ID: 15853577
[TBL] [Abstract][Full Text] [Related]
7. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group.
Adler CH; Sethi KD; Hauser RA; Davis TL; Hammerstad JP; Bertoni J; Taylor RL; Sanchez-Ramos J; O'Brien CF
Neurology; 1997 Aug; 49(2):393-9. PubMed ID: 9270567
[TBL] [Abstract][Full Text] [Related]
8. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
Inzelberg R; Schechtman E; Nisipeanu P
Drugs Aging; 2003; 20(11):847-55. PubMed ID: 12964891
[TBL] [Abstract][Full Text] [Related]
9. Ropinirole: a review of its use in the management of Parkinson's disease.
Matheson AJ; Spencer CM
Drugs; 2000 Jul; 60(1):115-37. PubMed ID: 10929932
[TBL] [Abstract][Full Text] [Related]
10. Ropinirole for levodopa-induced complications in Parkinson's disease.
Clarke CE; Deane KH
Cochrane Database Syst Rev; 2000; (3):CD001516. PubMed ID: 10908503
[TBL] [Abstract][Full Text] [Related]
11. The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease.
Schrag AE; Brooks DJ; Brunt E; Fuell D; Korczyn A; Poewe W; Quinn NP; Rascol O; Stocchi F
Clin Neuropharmacol; 1998; 21(3):169-75. PubMed ID: 9617508
[TBL] [Abstract][Full Text] [Related]
12. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Clarke CE; Deane KH
Cochrane Database Syst Rev; 2001; (1):CD001517. PubMed ID: 11279719
[TBL] [Abstract][Full Text] [Related]
13. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Clarke CE; Deane KH
Cochrane Database Syst Rev; 2000; 2001(3):CD001517. PubMed ID: 10908504
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacology of dopamine agonists in Parkinson's disease.
Lange KW
Drugs Aging; 1998 Nov; 13(5):381-9. PubMed ID: 9829165
[TBL] [Abstract][Full Text] [Related]
15. Dopamine agonists in Parkinson's disease.
Yamamoto M; Schapira AH
Expert Rev Neurother; 2008 Apr; 8(4):671-7. PubMed ID: 18416667
[TBL] [Abstract][Full Text] [Related]
16. [Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy].
Buchwald B; Angersbach D; Jost WH
Fortschr Neurol Psychiatr; 2007 Apr; 75(4):236-41. PubMed ID: 17427044
[TBL] [Abstract][Full Text] [Related]
17. High-dose ropinirole in advanced Parkinson's disease with severe dyskinesias.
Cristina S; Zangaglia R; Mancini F; Martignoni E; Nappi G; Pacchetti C
Clin Neuropharmacol; 2003; 26(3):146-50. PubMed ID: 12782917
[TBL] [Abstract][Full Text] [Related]
18. Combination of two different dopamine agonists in the management of Parkinson's disease.
Stocchi F; Berardelli A; Vacca L; Thomas A; De Pandis MF; Modugno N; Valente M; Ruggieri S
Neurol Sci; 2002 Sep; 23 Suppl 2():S115-6. PubMed ID: 12548370
[TBL] [Abstract][Full Text] [Related]
19. New pharmacotherapy for Parkinson's disease.
Gottwald MD; Bainbridge JL; Dowling GA; Aminoff MJ; Alldredge BK
Ann Pharmacother; 1997 Oct; 31(10):1205-17. PubMed ID: 9337447
[TBL] [Abstract][Full Text] [Related]
20. The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets.
Uchida S; Soshiroda K; Okita E; Kawai-Uchida M; Mori A; Jenner P; Kanda T
Eur J Pharmacol; 2015 Nov; 766():25-30. PubMed ID: 26415982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
